Phathom Pharmaceuticals (PHAT) Current Deferred Revenue (2023 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Current Deferred Revenue of $37.3 million for Q2 2026, up 73.2% year-over-year from $21.5 million in Q2 2025, and up 12.92% quarter-over-quarter from $33.0 million in Q1 2026.
Phathom Pharmaceuticals (PHAT) Current Deferred Revenue (2023 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Current Deferred Revenue for 4 consecutive years, with $37.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Current Deferred Revenue rose 73.2% year-over-year to $37.3 million; the TTM figure through Jun 2026 stood at $37.3 million (up 73.2% YoY), while the FY2025 annual figure was $27.2 million, up 37.78% from the prior year.
- Current Deferred Revenue advanced to $37.3 million in Q2 2026 per PHAT's latest filing, from $33.0 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $37.3 million in Q2 2026 and bottomed at $276000.0 in Q2 2023.
- Historically, Current Deferred Revenue has averaged $18.2 million across 4 years, with a median of $19.8 million in 2024.
- Annual changes were most pronounced in 2024 — Current Deferred Revenue jumped 3490.58% — and 2025, when it increased 4.79%.
- Phathom Pharmaceuticals' Current Deferred Revenue stood at $7.1 million in 2023, then surged by 178.12% to $19.8 million in 2024, then soared by 37.78% to $27.2 million in 2025, then jumped by 36.82% to $37.3 million in 2026.
- Business Quant data shows PHAT's Current Deferred Revenue at $37.3 million in Q2 2026, $33.0 million in Q1 2026, and $27.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Phathom Pharmaceuticals | 767.07 Mn | 581.73 Mn | 59.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.28 Mn |
| Mar 31, 2026 | 33.02 Mn |
| Dec 31, 2025 | 27.25 Mn |
| Sep 30, 2025 | 24.34 Mn |
| Jun 30, 2025 | 21.53 Mn |
| Mar 31, 2025 | 17.27 Mn |
| Dec 31, 2024 | 19.78 Mn |
| Sep 30, 2024 | 20.19 Mn |
| Jun 30, 2024 | 9.91 Mn |
| Mar 31, 2024 | 16.48 Mn |
| Dec 31, 2023 | 7.11 Mn |
| Sep 30, 2023 | 2.39 Mn |
| Jun 30, 2023 | 276,000.00 |